Screener
Gyre Therapeutics, Inc. GYRE Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Diluted | $$(0.03)) | $$(0.03)) |
| Weighted average shares used in calculating net (loss) income per share attributable to common stockholders: | ||
| Basic | 89,119,344 | 87,295,099 |
| Diluted | 89,203,138 | 87,430,167 |
| Other comprehensive (loss) income: | ||
| Reclassification adjustment for gains (loss) included in net (loss) income | 12 | 8) |
| Unrealized loss on short-term investments | (22)) | (4)) |
| Foreign currency translation adjustments | 348 | 547 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s shares (diluted)?
- Gyre Therapeutics, Inc. (GYRE) reported shares (diluted) of 100.6M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Gyre Therapeutics, Inc.'s shares (diluted) increased by 12.8% year-over-year, from 89.2M to 100.6M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s shares (diluted) has grown at a 34.5% compound annual growth rate (CAGR), from 121.8M to 398.3M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Gyre Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude